Filing Details

Accession Number:
0001178913-21-003807
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-12-08 07:29:37
Reporting Period:
2021-12-06
Accepted Time:
2021-12-08 07:29:37
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1534248 Chemomab Therapeutics Ltd. CMMB Pharmaceutical Preparations (2834) 813676773
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1840006 Harris Neil Cohen C/O Chemomab Therapeutics Ltd.,
1 Kendall Sq, Bldg 1400E, Ste 14-105
Cambridge MA 02139
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
American Depositary Shares Acquisiton 2021-12-06 2,000 $7.43 4,409 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
American Depositary Shares Option to Purchase American Depositary Shares $27.26 2031-04-19 11,884 11,884 Direct
American Depositary Shares Option to Purchase American Depositary Shares $13.17 2030-03-15 688 688 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2031-04-19 11,884 11,884 Direct
2030-03-15 688 688 Direct
Footnotes
  1. Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
  2. The ADSs are held of record directly by the Phoenix Insurance Company Ltd. (Naftali Neil Cohen) (the "IRA"), which is self-managed by the Reporting Person. The Reporting person is the sole beneficiary of the IRA and may be deemed to have sole voting and dispositive power with respect to the ADSs held by IRA.
  3. No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
  4. These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service.
  5. These options vest and become exercisable as follows: 1/3 vest on July 16, 2021, and the remaining options vest on a quarterly basis for the following eight quarters, subject to the Reporting Person's continued service.